Home > Insider Trading > Filing (0000899243-19-005883)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
730272	Repligen Corp	RGEN	Biological Products, (No Disgnostic Substances) (2836)	042729386

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1733143	Ralf Kuriyel	C/O Repligen Corporation 41 Seyon St., Bldg 1, Ste 100 Waltham MA 02453	Senior Vp, R&D	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2019-02-28	4,234	$0.00	16,528	No	4	A	Direct
Common Stock	Disposition	2019-02-28	185	$59.16	16,343	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	A	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (Right to Buy)	Acquisiton	2019-02-28	4,042	$0.00	4,042	$59.52

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
4,042		2029-02-28	No	4	A	Direct

Footnotes

Mr. Kuriyel was awarded 4,234 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of Repligen Corporation's Common Stock. The restricted stock units vest in equal annual installments over a three-year period beginning on the first anniversary of the grant date. The restricted stock units may be settled only be delivering shares of Repligen Corporation's Common Stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance.
Sale of 185 shares in the open market to cover tax liability resulting from the release of restricted stock units.
One third of the stock options will vest and become exercisable annually on February 28, 2020, February 28, 2021 and February 28, 2022.